Cardiovascular involvement in systemic autoimmune diseases
Introduction
Systemic autoimmune diseases make up a family of conditions that share common pathogenetic mechanisms and multi-organ involvement including the heart. Autoimmune diseases occur because the physiological tolerance to self-antigens is lost and, although circulating antibodies do not always play a pathogenetic role, they represent specific markers of ongoing tissue damage. In the case of systemic autoimmune diseases, the autoantibodies are against ubiquitous antigens (i.e. nuclear antigens in systemic lupus erythematosus or SLE), and the tissue damage is generalised.
Systemic autoimmune diseases affect many patients with rheumatoid arthritis (RA), SLE, primary antiphospholipid syndrome (APS), systemic sclerosis and systemic vasculitis, in whom one of the leading causes of morbidity and mortality is cardiovascular disease, which is associated with the development of accelerated atherosclerosis [1], [2]: for example, cardiovascular mortality accounts for 40–50% of all deaths in RA [3]. Furthermore, cardiovascular disease seems to occur at a younger age than in the general population, is often asymptomatic (at least in the early stages) and, in addition to traditional risk factors, also involves specific risk factors. In particular, the excess cardiovascular mortality and morbidity can be explained by chronic inflammation, the duration and activity of the autoimmune disease, and the effects of immunosuppressive therapy (glucocorticoids and methotrexate) [4]. Wolfe et al. [5] have observed that minimal disease activity and a short disease duration are associated with better outcomes in RA.
All of the components of the heart can be affected by a number of pathogenetic mechanisms that may involve the valves, the coronary arteries, the conduction system, or the myocardium, endocardium or pericardium. The clinical manifestations of cardiac involvement include: pericarditis, myocarditis and myocardial fibrosis, rhythm and conduction disturbances, coronaritis with ischemic heart disease, valvular diseases, pulmonary hypertension, syncope, and diastolic or systolic heart failure [1], [6].
It has recently been recognised that chronic inflammation plays an important role in the development of atherosclerotic plaque [7], [8], [9], and the prime mover in this process seems to be endothelial dysfunction [10], which is largely characterised by a reduction in nitric oxide (NO) production by NO synthase. Asymmetric dimethyl arginine (ADMA) is an endogenous inhibitor of NO synthase and has recently emerged as a novel marker of cardiovascular risk; it has already been demonstrated that plasma ADMA levels are high in RA patients [11]. Moreover, it has been shown that anti-rheumatic drugs reduce systemic inflammation and may improve endothelial dysfunction [12], and the same effect has been observed after statin therapy [13], [14].
As autoimmune diseases are characterised by a high degree of cardiovascular risk, and cardiac involvement is associated with adverse outcomes and a poor prognosis, the early identification of patients at higher risk is essential. Knowing the mechanisms responsible for cardiovascular damage in systemic autoimmune diseases is an important step in choosing appropriate drugs that can block/slow the development of atherosclerosis.
Section snippets
Imaging techniques
The early phases of cardiovascular involvement in patients with autoimmune diseases may be clinically silent, with only the presence of a microcirculation disorder (Table 1). The diagnostic imaging techniques capable of detecting morphological cardiac damage can be divided into:
- 1.
non invasive (transthoracic echocardiography, tissue doppler imaging)
- 2.
semi-invasive (transthoracic stress echocardiography, transesophageal echocardiography)
- 3.
computed tomography and coronary magnetic resonance angiography
- 4.
Effects of anti-rheumatic therapy
Evidence has recently emerged indicating that the effects of anti-rheumatic therapy may go beyond controlling inflammation and disease activity, including the endothelial effects of anti-tumor necrosis factor (TNF) α agents and the effects of conventional therapy and biological drugs on vascular function.
Hurlimann et al. [12] found that TNFα antagonism not only reduces RA activity but also improves endothelial function. They also observed that the reduction in local and systemic inflammation
Conclusions
As patients with systemic autoimmune diseases are at higher risk of developing cardiovascular diseases than the general population, it is essential to detect endothelial dysfunction and impaired coronary microcirculation earlier in asymptomatic subjects.
Coronary angiography remains the gold standard for the diagnosis of coronary stenosis, but new, non invasive and more reliable diagnostic techniques have been introduced into clinical practice to detect sub-clinical microcirculation
Take-home messages
- •
Patients with systemic autoimmune diseases are at increased risk of developing cardiovascular diseases
- •
The early phases of cardiovascular involvement in patients with autoimmune diseases may be clinically silent, with only a microcirculation disorder present.
- •
Echocardiography with its numerous applications (CFR evaluation, TDI, transesophageal) seems to be the most suitable means of screening.
- •
Common carotid IMT measured by means of carotid ultrasound may provide additional information that is
References (40)
- et al.
Cardiac manifestations in antiphospholipid syndrome
Autoimmun Rev
(2007) - et al.
The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia
J Autoimmun
(2007) - et al.
Coronary involvement in Takayasu's arteritis
Autoimmun Rev
(2007) - et al.
OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients
Autoimmun Rev
(2007) - et al.
IgA antibodies to beta2-glycoprotein I and atherosclerosis
Autoimmun Rev
(2006) - et al.
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis
J Am Coll Cardiol
(2007) - et al.
Insights into atherosclerosis therapy in antiphospholipid syndrome
Autoimmun Rev
(2007) - et al.
Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a noninvasive, rapid and effective method for coronary flow reserve assessment
J Am Coll Cardiol
(1999) - et al.
Usefulness of coronary flow reserve over regional wall motion when added to dual-imaging dipyridamole echocardiography
Am J Cardiol
(2003) - et al.
Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome
Am J Cardiol
(2005)
Ultrasound assessment of internal carotid artery stenosis
Clin Radiol
Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis
Atherosclerosis
Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine
J Am Coll Cardiol
Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment
Am J Cardiol
Cardiac involvement in systemic inflammatory diseases
Eur Heart J
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors
Arthritis Rheum
Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis
Arthritis Rheum
Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis
Circulation
Forearm hemodynamics, arterial stiffness and microcirculatory reactivity in RA
J Hypertens
Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in Systemic Lupus Erythematosus
J Rheumatol
Cited by (93)
Introduction on autoimmune rheumatic diseases
2023, Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic DiseasesExercise tolls the bell for key mediators of low-grade inflammation in dysmetabolic conditions
2021, Cytokine and Growth Factor ReviewsNucleic Acid Sensors as Therapeutic Targets for Human Disease
2020, ImmunityCitation Excerpt :HCQ is also being explored for potential beneficial effects in the setting of myocardial infarction, both in reducing the recurrence of cardiovascular events among myocardial infraction patients and whether it can affect cardiovascular risk factors and systemic inflammation (NCT02648464). Given the increased risk for cardiovascular involvement in patients with RA or SLE (Sitia et al., 2009; Giannelou and Mavragani, 2017; Blum and Adawi, 2019), this study may have important implications for these diseases. ODNs were initially designed to directly bind and antagonize endosomal TLRs as a therapeutic strategy to treat SLE.
Physical inactivity and sedentary behavior: Overlooked risk factors in autoimmune rheumatic diseases?
2017, Autoimmunity ReviewsCitation Excerpt :Whether this holds true in autoimmune rheumatic disease remains uncertain (Fig. 1, panel C). We compiled evidence to show that estimates of physical inactivity and sedentary behavior in autoimmune rheumatic diseases are generally comparable to other rheumatic diseases as well as chronic conditions in which lack of physical activity and excess of sedentary behavior are well-known predictors of morbimortality [17–19]. In addition, there is also evidence that both physical inactivity and sedentary behavior may be associated with poor health-related outcomes (e.g., worsen disease symptoms and low functionality) in autoimmune rheumatic diseases [44–46,60,61,70,79,80,101].